Drug Profile
Baliforsen - Ionis Pharmaceuticals
Alternative Names: BIIB 065; IONIS-DMPK-2.5Rx; ISIS 598769; ISIS DMPKRx; ISIS-DMPK-2.5RxLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myotonic dystrophy
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-II for Myotonic dystrophy in USA (SC) (Ionis Pharmaceuticals pipeline, September 2021)
- 01 Aug 2016 Ionis Pharmaceuticals completes a phase-I/II clinical trial in Myotonic dystrophy in USA (SC) (NCT02312011)
- 15 Jun 2016 Phase-II clinical trials in Myotonic dystrophy in USA (SC) (Ionis Pharmaceuticals pipeline, June 2016)